VisCardia

Executive Summary

VisCardia Inc. is a privately held medical device company developing Synchronized Diaphragmatic Stimulation (SDS) therapy, a novel, minimally invasive implantable treatment for heart failure with reduced ejection fraction (HFrEF). The therapy aims to improve cardiac function by stimulating the diaphragm in synchrony with the heart's rhythm, potentially offering a new option for the large population of heart failure patients who remain symptomatic despite optimal medical therapy. Founded in 2014 and headquartered in Portland, Oregon, VisCardia has completed initial clinical studies in Europe, demonstrating safety and early signals of efficacy. The company is now focused on advancing its regulatory pathway and preparing for pivotal trials in the United States. VisCardia operates in a competitive landscape of heart failure devices, including cardiac resynchronization therapy and implantable hemodynamic monitors, but its unique mechanism of diaphragmatic stimulation differentiates it. With heart failure affecting over 6 million Americans and growing, the market opportunity is substantial. The company is expected to pursue FDA approval through the Investigational Device Exemption (IDE) process. Key near-term milestones include securing additional financing to support larger trials and publishing longer-term follow-up data from its European studies. While the technology is early-stage and regulatory risks exist, VisCardia's innovative approach and initial clinical promise position it as an intriguing candidate in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q4 2026FDA IDE Approval for US Pivotal Trial70% success
• Q3 2026Series B or C Financing Round60% success
• Q2 2026Publication of European Clinical Study Results80% success